Since p53 therapy for GBM is not very efficient due to the presence of the blood brain barrier (BBB), a systemic nanodelivery platform (scL) for tumor-specific targeting (primary and metastatic) has been developed by Kim et al. It has been observed that the combination of scL-p53 and TMZ increased the antibrain tumor efficacy of TMZ [245]. Here, TP53 is linked to neoplasm.